Doron Therapeutics

Doron Therapeutics is a clinical-stage biotechnology company focused on degenerative musculoskeletal diseases, developing a Phase 3 ready-to-use intra-articular biologic derived from placental tissue. The lead product, MOTYS™, contains numerous beneficial growth factors, and preclinical data suggest it has effective anti-inflammatory, tissue-protective, and regenerative capabilities that are critical for treating the progressive and degenerative disease of osteoarthritis.